Enanta Pharmaceuticals, Inc. (ENTA)

US — Healthcare Sector
Peers: GLUE  DSGN  HOWL  IKNA  STOK  CRNX  INBX  MRUS  LYEL  KRON  IPSC  EWTX  CCCC  MLYS  CGEM  THRX  RVMD 

Automate Your Wheel Strategy on ENTA

With Tiblio's Option Bot, you can configure your own wheel strategy including ENTA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ENTA
  • Rev/Share 3.0186
  • Book/Share 4.3801
  • PB 1.3538
  • Debt/Equity 0.6279
  • CurrentRatio 5.2857
  • ROIC -0.3565

 

  • MktCap 126763238.0
  • FreeCF/Share -3.8511
  • PFCF -1.5414
  • PE -1.3134
  • Debt/Assets 0.1818
  • DivYield 0
  • ROE -0.7983

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?
ENTA
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive

The consensus price target hints at an 189.6% upside potential for Enanta Pharmaceuticals (ENTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Read More
image for news Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade
ENTA
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive

Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade

About Enanta Pharmaceuticals, Inc. (ENTA)

  • IPO Date 2013-03-21
  • Website https://www.enanta.com
  • Industry Biotechnology
  • CEO Dr. Jay R. Luly Ph.D.
  • Employees 131
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.